Antibodies from Llama helps world medicine in fight against the Coronavirus

Grippe et vaccin Sciences et Avenir

The antibodies produced by the Llama could be used against COVID-19.


You can also watch here number of infection with Coronavirus Updated (Live) on worldometers

A study by the University of Texas, USA, led to the discovery of antibodies that can "bind" to one of the key proteins on the surface of the coronavirus. The researchers explain that these antibodies attach to those proteins that allow SARS-CoV-2 to infect cells in the host organism. In addition to this discovery with significant potential against the pandemic we are going through, scientists also point to the unusual source from which they obtained these antibodies: a blade called Winter, notes Neuroscience News.

Antibodies for medicine génération et ingénierie MI-mAbs

This is one of the first known antibodies that can neutralize SARS-CoV-2, said Jason McLellan, a member of the University of Texas Department of Molecular Bioscience and co-author of the study.

The effectiveness of these antibodies, called VHH-72, has been proven in laboratory cultures, and researchers are now focusing on studying their effects in laboratory animals. If these tests prove conclusive then scientists could receive the necessary approvals to start human testing.

Single-Antibodies Fusion explained Free Full-Text MDPI

"Vaccines should be given a month or two before infection to provide protection," said Dr. McLellan. "In the case of antibody therapies, we administer protective antibodies directly to a patient and thus, immediately after treatment, they should be protected. Antibodies could also be used to treat someone who is already ill to reduce the severity of the disease, ” he added.

Structural Basis for Potent Neutralization of Betacoronaviruses ScienceDirect.com

Scientists explain that when faced with an infection, the immune system of the lamellae produces two types of antibodies: one of them is similar to those produced by the human immune system and a type of small antibody, VHH- 72. The latter have only a quarter of the former and, in theory, could be administered with an inhaler. Scientists believe that such a method of administration could be extremely effective because it "directly" attacks the site of infection.



You may also like:

• Coronavirus: Global Food Crisis Will NOT Kill US !

• What are zoonotic diseases? Pathogens that spread between animals amd humans

The study was published in Cell.

The World Health Organization has made a list of the most dangerous antibiotic-resistant bacteria

National Institute of Allergy and Infectious Diseases (NIAID)

For the first time ever, the World Health Organization has drawn up a list of the highest priority needs for new antibiotics — marching orders, it hopes, for the pharmaceutical industry.

The list, which was released Monday, enumerates 12 bacterial threats, grouping them into three categories: critical, high, and medium.

"Antibiotic resistance is growing and we are running out of treatment options. If we leave it to market forces alone, the new antibiotics we most urgently need are not going to be developed in time," said Dr. Marie-Paule Kieny, the WHO's assistant director-general for health systems and innovation.

"The pipeline is practically dry."

Three bacteria were listed as critical:

• Acinetobacter baumannii bacteria that are resistant to important antibiotics called carbapenems. These are highly drug resistant bacteria that can cause a range of infections for hospitalized patients, including pneumonia, wound, or blood infections.

U.S. Centers for Disease Control and Prevention

• Pseudomonas aeruginosa, which are resistant to carbapenems. These bacteria can cause skin rashes and ear infectious in healthy people but also severe blood infections and pneumonia when contracted by sick people in the hospital.

• Enterobacteriaceae that are resistant to both carbepenems and another class of antibiotics, cephalosporins. This family of bacteria live in the human gut and includes bugs such as E. coli and Salmonella.

Notably missing from the list is the bacterium that causes tuberculosis. That was not included, Kieny said, because the need for new antibiotics to treat it has already been designated the highest priority.

Although mounting concerns about the worsening problem of antibiotic resistance have reinvigorated research efforts, producing new antibiotics is an expensive and challenging task.

The international team of experts who drew up the new list urged researchers and pharmaceutical companies to focus their efforts on a type of bacteria known as Gram negatives. (The terminology relates to how the bacteria respond to a stain — developed by Hans Christian Gram — used to make them easier to see under a microscope.)

Dr. Nicola Magrini, a scientist with the WHO's department of innovation, access and use of essential medicines, said pharmaceutical companies have recently spent more efforts trying to find antibiotics for Gram positive bacteria, perhaps because they are easier and less costly to develop.

Microscopic image of gram-negative Pseudomonas aeruginosa bacteria (pink-red rods) Credit: wikipedia

Gram negative bacteria typically live in the human gut, which means when they cause illness it can be serious bloodstream infections or urinary tract infections. Gram positive bacteria are generally found outside the body, on the skin or in the nostrils.

Kieny said the 12 bacteria featured on the priority list were chosen based on the level of drug resistance that already exists for each, the numbers of deaths they cause, the frequency with which people become infected with them outside of hospitals, and the burden these infections place on health care systems.

Paradoxically, though, she and colleagues from the WHO could not provide an estimate of the annual number of deaths attributable to antibiotic-resistant infections. The international disease code system does not currently include a code for antibiotic-resistant infections; it is being amended to include one.

The critical pathogens are ones that cause severe infections and high mortality in hospital patients, Kieny said. While they are not as common as other drug-resistant infections, they are costly in terms of health care resources needed to treat infected patients and in lives lost.

Six others were listed as high priority for new antibiotics. That grouping represents bacteria that cause a large number of infections in otherwise healthy people. Included there is the bacteria that causes gonorrhea, for which there are almost no remaining effective treatments.

Three other bacteria were listed as being of medium priority, because they are becoming increasingly resistant to available drugs. This group includes Streptococcus pneumoniae that is not susceptible to penicillin. This bacterium causes pneumonia, ear and sinus infections, as well as meningitis and blood infections.

The creation of the list was applauded by others working to combat the rise of antibiotic resistance.

"This priority pathogens list, developed with input from across our community, is important to steer research in the race against drug resistant infection — one of the greatest threats to modern health," said Tim Jinks, head of drug-resistant infections for the British medical charity Wellcome Trust.

"Within a generation, without new antibiotics, deaths from drug-resistant infection could reach 10 million a year. Without new medicines to treat deadly infection, lifesaving treatments like chemotherapy and organ transplant, and routine operations like caesareans and hip replacements, will be potentially fatal."

The full list is:

Priority 1: Critical

1. Acinetobacter baumannii, carbapenem-resistant

2. Pseudomonas aeruginosa, carbapenem-resistant

3. Enterobacteriaceae, carbapenem-resistant, ESBL-producing

Priority 2: High

4. Enterococcus faecium, vancomycin-resistant

5. Staphylococcus aureus, methicillin-resistant, vancomycin-intermediate and resistant

6. Helicobacter pylori, clarithromycin-resistant

7. Campylobacter spp., fluoroquinolone-resistant

8. Salmonellae, fluoroquinolone-resistant

9. Neisseria gonorrhoeae, cephalosporin-resistant, fluoroquinolone-resistant

Priority 3: Medium

10. Streptococcus pneumoniae, penicillin-non-susceptible

11. Haemophilus influenzae, ampicillin-resistant

12. Shigella spp., fluoroquinolone-resistant

Other articles on the same theme:

• A medicine that promises to treat Alzheimer has been tested on humans

• Cellular reprogramming has been used to reverse ageing

• A new organ was discovered in the human body

• Yoshinori Ohsumi won the Nobel Prize for Medicine in 2016

Story source: 

 

The above post is reprinted from materials provided by Businessinsider . Note: Materials may be edited for content and length.